Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 71,500 shares, a decline of 21.5% from the February 13th total of 91,100 shares. Based on an average daily volume of 36,300 shares, the short-interest ratio is presently 2.0 days. Approximately 0.8% of the shares of the stock are short sold.

Hedge Funds Weigh In On Daré Bioscience

Several large investors have recently modified their holdings of the stock. AMH Equity Ltd increased its position in shares of Daré Bioscience by 50.0% during the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 50,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 3,593 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Daré Bioscience by 6.7% during the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 4,300 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Daré Bioscience during the 4th quarter valued at approximately $52,000. Institutional investors own 6.70% of the company’s stock.

Daré Bioscience Stock Performance

NASDAQ:DARE traded down $0.02 during trading hours on Wednesday, reaching $2.96. The stock had a trading volume of 12,566 shares, compared to its average volume of 45,827. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56. The company has a 50 day moving average price of $3.13 and a two-hundred day moving average price of $3.32. The stock has a market capitalization of $25.71 million, a PE ratio of -5.00 and a beta of 1.38.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.